vs
REPLIGEN CORP（RGEN）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是REPLIGEN CORP的1.1倍（$217.4M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 1.4%，领先5.3%），REPLIGEN CORP同比增速更快（13.6% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 3.0%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
RGEN vs RPD — 直观对比
营收规模更大
RPD
是对方的1.1倍
$197.9M
营收增速更快
RGEN
高出13.1%
0.5%
净利率更高
RGEN
高出5.3%
1.4%
自由现金流更多
RPD
多$18.9M
$17.6M
两年增速更快
RGEN
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.9M | $217.4M |
| 净利润 | $13.3M | $3.1M |
| 毛利率 | 52.5% | 68.9% |
| 营业利润率 | 9.0% | 1.0% |
| 净利率 | 6.7% | 1.4% |
| 营收同比 | 13.6% | 0.5% |
| 净利润同比 | 143.9% | 44.1% |
| 每股收益（稀释后） | $0.24 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGENRPD
| Q4 25 | $197.9M | $217.4M | ||
| Q3 25 | $188.8M | $218.0M | ||
| Q2 25 | $182.4M | $214.2M | ||
| Q1 25 | $169.2M | $210.3M | ||
| Q4 24 | $174.1M | $216.3M | ||
| Q3 24 | $154.9M | $214.7M | ||
| Q2 24 | $154.1M | $208.0M | ||
| Q1 24 | $151.3M | $205.1M |
净利润RGENRPD
| Q4 25 | $13.3M | $3.1M | ||
| Q3 25 | $14.9M | $9.8M | ||
| Q2 25 | $14.9M | $8.3M | ||
| Q1 25 | $5.8M | $2.1M | ||
| Q4 24 | $-30.3M | $2.2M | ||
| Q3 24 | $-654.0K | $15.4M | ||
| Q2 24 | $3.3M | $6.5M | ||
| Q1 24 | $2.1M | $1.4M |
毛利率RGENRPD
| Q4 25 | 52.5% | 68.9% | ||
| Q3 25 | 53.2% | 70.2% | ||
| Q2 25 | 50.0% | 70.6% | ||
| Q1 25 | 53.6% | 71.7% | ||
| Q4 24 | 26.1% | 69.5% | ||
| Q3 24 | 50.0% | 70.6% | ||
| Q2 24 | 49.8% | 70.7% | ||
| Q1 24 | 49.5% | 70.3% |
营业利润率RGENRPD
| Q4 25 | 9.0% | 1.0% | ||
| Q3 25 | 8.9% | 2.7% | ||
| Q2 25 | 7.6% | 1.6% | ||
| Q1 25 | 3.9% | -0.0% | ||
| Q4 24 | -17.7% | 3.4% | ||
| Q3 24 | -5.1% | 6.0% | ||
| Q2 24 | 1.0% | 2.5% | ||
| Q1 24 | 1.3% | 4.7% |
净利率RGENRPD
| Q4 25 | 6.7% | 1.4% | ||
| Q3 25 | 7.9% | 4.5% | ||
| Q2 25 | 8.2% | 3.9% | ||
| Q1 25 | 3.4% | 1.0% | ||
| Q4 24 | -17.4% | 1.0% | ||
| Q3 24 | -0.4% | 7.2% | ||
| Q2 24 | 2.2% | 3.1% | ||
| Q1 24 | 1.4% | 0.7% |
每股收益（稀释后）RGENRPD
| Q4 25 | $0.24 | $0.05 | ||
| Q3 25 | $0.26 | $0.15 | ||
| Q2 25 | $0.26 | $0.13 | ||
| Q1 25 | $0.10 | $0.03 | ||
| Q4 24 | $-0.55 | $0.08 | ||
| Q3 24 | $-0.01 | $0.21 | ||
| Q2 24 | $0.06 | $0.09 | ||
| Q1 24 | $0.04 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $767.6M | $474.7M |
| 总债务越低越好 | $542.2M | — |
| 股东权益账面价值 | $2.1B | $154.7M |
| 总资产 | $2.9B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
现金及短期投资RGENRPD
| Q4 25 | $767.6M | $474.7M | ||
| Q3 25 | $748.7M | $407.1M | ||
| Q2 25 | $708.9M | $511.7M | ||
| Q1 25 | $697.2M | $493.5M | ||
| Q4 24 | $757.4M | $521.7M | ||
| Q3 24 | $784.0M | $443.7M | ||
| Q2 24 | $809.1M | $442.6M | ||
| Q1 24 | $780.6M | $411.7M |
总债务RGENRPD
| Q4 25 | $542.2M | — | ||
| Q3 25 | $537.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $525.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RGENRPD
| Q4 25 | $2.1B | $154.7M | ||
| Q3 25 | $2.1B | $127.2M | ||
| Q2 25 | $2.1B | $90.4M | ||
| Q1 25 | $2.0B | $52.7M | ||
| Q4 24 | $2.0B | $17.7M | ||
| Q3 24 | $2.0B | $-5.1M | ||
| Q2 24 | $2.0B | $-52.6M | ||
| Q1 24 | $2.0B | $-86.4M |
总资产RGENRPD
| Q4 25 | $2.9B | $1.7B | ||
| Q3 25 | $2.9B | $1.7B | ||
| Q2 25 | $2.9B | $1.6B | ||
| Q1 25 | $2.9B | $1.6B | ||
| Q4 24 | $2.8B | $1.7B | ||
| Q3 24 | $2.8B | $1.6B | ||
| Q2 24 | $2.9B | $1.5B | ||
| Q1 24 | $2.8B | $1.5B |
负债/权益比RGENRPD
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.7M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $17.6M | $36.4M |
| 自由现金流率自由现金流/营收 | 8.9% | 16.8% |
| 资本支出强度资本支出/营收 | 4.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.93× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $93.9M | $146.2M |
8季度趋势，按日历期对齐
经营现金流RGENRPD
| Q4 25 | $25.7M | $37.6M | ||
| Q3 25 | $48.1M | $39.0M | ||
| Q2 25 | $28.6M | $47.5M | ||
| Q1 25 | $15.0M | $29.8M | ||
| Q4 24 | $39.2M | $63.8M | ||
| Q3 24 | $49.3M | $44.0M | ||
| Q2 24 | $42.2M | $32.9M | ||
| Q1 24 | $44.7M | $31.1M |
自由现金流RGENRPD
| Q4 25 | $17.6M | $36.4M | ||
| Q3 25 | $43.4M | $34.8M | ||
| Q2 25 | $21.5M | $46.6M | ||
| Q1 25 | $11.4M | $28.4M | ||
| Q4 24 | $33.6M | $62.6M | ||
| Q3 24 | $42.3M | $42.6M | ||
| Q2 24 | $37.4M | $32.6M | ||
| Q1 24 | $36.4M | $30.4M |
自由现金流率RGENRPD
| Q4 25 | 8.9% | 16.8% | ||
| Q3 25 | 23.0% | 16.0% | ||
| Q2 25 | 11.8% | 21.8% | ||
| Q1 25 | 6.8% | 13.5% | ||
| Q4 24 | 19.3% | 28.9% | ||
| Q3 24 | 27.3% | 19.9% | ||
| Q2 24 | 24.3% | 15.7% | ||
| Q1 24 | 24.0% | 14.8% |
资本支出强度RGENRPD
| Q4 25 | 4.1% | 0.5% | ||
| Q3 25 | 2.5% | 1.9% | ||
| Q2 25 | 3.9% | 0.4% | ||
| Q1 25 | 2.1% | 0.6% | ||
| Q4 24 | 3.2% | 0.5% | ||
| Q3 24 | 4.5% | 0.6% | ||
| Q2 24 | 3.1% | 0.1% | ||
| Q1 24 | 5.5% | 0.3% |
现金转化率RGENRPD
| Q4 25 | 1.93× | 12.01× | ||
| Q3 25 | 3.23× | 3.97× | ||
| Q2 25 | 1.92× | 5.70× | ||
| Q1 25 | 2.57× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | 12.70× | 5.03× | ||
| Q1 24 | 21.35× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGEN
暂无分部数据
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
